---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-042886"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:24:47.184305+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences appoints Glenn Reicin as CFO; reaffirms 2026 revenue guidance of $1.0-$1.04B

## Summary
- Sandip Kapadia steps down as CFO effective April 14, 2026 to pursue other career opportunities.
- Glenn Reicin appointed CFO; previously CFO at Eccogene and Alladapt, Managing Director at Skyline Ventures.
- New CFO: $500K base salary, 50% target bonus, $3M option grant vesting over four years.
- Company reiterates 2026 net product revenue guidance of $1.0-$1.04 billion from WAKIX sales.

## SEC filing metadata
- accession: 0001104659-26-042886
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465926042886/0001104659-26-042886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465926042886/hrmy-20260414x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-042886
- JSON: https://secwatch.observer/filing/0001104659-26-042886.json
- Plain text: https://secwatch.observer/filing/0001104659-26-042886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.